Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 13, 2010

OriGene Picks Up Gene-Synthesis Firm Blue Heron Biotechnology

OriGene Picks Up Gene-Synthesis Firm Blue Heron Biotechnology

Company’s expertise will bolster Origene’s gene-based services. [© Gernot Krautberger - Fotolia.com]

  • OriGene Technologies is acquiring Blue Heron Biotechnology, which has concentrated on gene synthesis since 1999. OriGene believes that coupling Blue Heron’s focus with its own collection of human cDNA clones will provide the life science community with a variety of product solutions including protein and antibody optimization.

    Blue Heron says that it supplies synthetic DNA to the majority of the top 20 pharma and biotech companies worldwide. It provided DNA fragments to develop the first synthetic cell for the J. Craig Venter Institute.

    Blue Heron is also part of a recently established consortium that was set up to promote biosecurity in the gene-synthesis industry. Along with DNA2.0, GeneArt, GenScript, and Integrated DNA Technologies, the firm formed the International Gene Synthesis Consortium (IGSC).

    Their “Harmonized Screening Protocol for Gene Sequence & Customer Screening to Promote Biosecurity” establishes five core components that each IGSC company will apply to promote the safe use of synthetic genes. These include screening of every synthetic gene order against a regulated pathogen database, screening of each potential gene-synthesis customer, creating more robust record keeping, reservation of the right to refuse an order, and compliance with variance laws and regulations.

Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »